Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ERN1 | O75460 | 8/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | CES1 | P23141 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 2/20 | 0.31 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31088903 | 0.92 | PRKDC (0.38) | PRKDCALDH1A1TSHRERN1LMNA | |
| SCHEMBL1517367 | 0.92 | PRKDC (0.38) | PRKDCALDH1A1TSHRERN1LMNA | |
| SCHEMBL15428162 | 0.83 | PRKDC (0.47) | PRKDCALDH1A1TSHRERN1LMNA | |
| SCHEMBL633623 | 0.82 | ERN1 (0.45) | PRKDCERN1LMNAKDM1AKDM1B | |
| SCHEMBL12375394 | 0.82 | ALDH1A1 (0.41) | ALDH1A1TSHRERN1LMNASMN1; SMN2 | |
| SCHEMBL3847770 | 0.80 | ALDH1A1 (0.46) | PRKDCALDH1A1TSHRERN1LMNA | |
| SCHEMBL29447325 | 0.80 | ALDH1A1 (0.46) | PRKDCALDH1A1TSHRERN1LMNA | |
| SCHEMBL365835 | 0.80 | ALDH1A1 (0.39) | ALDH1A1TSHRERN1SMN1; SMN2GRIA1 | |
| SCHEMBL25037161 | 0.79 | TSHR (0.41) | ALDH1A1TSHRERN1SMN1; SMN2GRIA1 | |
| SCHEMBL1405920 | 0.79 | KDM1A (0.31) | KDM1AKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | SANOFI (FR) | 2026-04-28 | — | — | US | disclosed |
| EP-4271674-B9 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12570642-B2 | GLP-IR modulating compounds | GILEAD SCIENCES, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| EP-4691554-A2 | GLP-1R MODULATING COMPOUNDS | Gilead Sciences, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| EP-4271672-B1 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| EP-4271674-B3 | CARBOXY-BENZIMIDAZOLE GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2025-12-03 | — | — | EP | disclosed |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | FORWARD THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250312352-A1 | GLP-1R MODULATING COMPOUNDS | GILEAD SCIENCES, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4622981-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | Forward Therapeutics, Inc. (US) | 2025-10-01 | — | — | EP | disclosed |
| US-12384808-B2 | Modulators of TNF-α activity | FORWARD THERAPEUTICS, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| EP-2433940-B1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2014-09-24 | — | — | EP | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | LABORATOIRES FOURNIER SA (FR) | 2012-09-13 | — | — | US | disclosed |
| EP-2475642-A1 | USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE | Laboratoires Fournier S.A. (FR) | 2012-07-18 | — | — | EP | disclosed |
| CN-102596906-A | Use of indole derivatives as NURR-1 activators as agents for the treatment of Parkinson's disease | FOURNIER LAB SA | 2012-07-18 | — | — | CN | disclosed |
| EP-2433940-A1 | SPIROIMIDAZOLONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2012-03-28 | — | — | EP | disclosed |
| WO-2011030068-A1 | USE OF INDOLE DERIVATIVES AS NURR-1 ACTIVATORS FOR THE APPLICATION THEREOF AS A MEDICAMENT FOR THE TREATMENT OF PARKINSON'S DISEASE | LABORATOIRES FOURNIER SA (FR) | 2011-03-17 | — | — | WO | disclosed |
| WO-2008137102-A2 | METHODS OF MODULATING AMYLOID BETA AND COMPOUNDS USEFUL THEREFOR | TORREYPINES THERAPEUTICS, INC. (US) | 2008-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612360-B2 | Substituted 6,7-dihydro-5H-benzo[7]annulene compounds and their derivatives, processes for their preparation and therapeutic uses thereof | ESRRA, FSHR, GPER1 | PRKDC 3652/4885ALDH1A1 1356/4885TSHR 84/4885 |
| US-20120232070-A1 | Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease | NCOR1, NR0B1, MTNR1A | PRKDC 4453/4885ALDH1A1 1522/4885TSHR 95/4885 |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | PRKDC 3065/4885ALDH1A1 836/4885TSHR 914/4885 |
| US-20250312352-A1 | GLP-1R MODULATING COMPOUNDS | GLP1R, GIPR, GPR119 | PRKDC 4361/4885ALDH1A1 3556/4885TSHR 120/4885 |
| US-12384808-B2 | Modulators of TNF-α activity | TNF, NFKBIA, TNFRSF1A | PRKDC 1146/4885ALDH1A1 2291/4885TSHR 3067/4885 |
| US-20250333429-A1 | MODULATORS OF TNF-ALPHA ACTIVITY | TNF, NFKBIA, TNFRSF1A | PRKDC 1015/4885ALDH1A1 2563/4885TSHR 2908/4885 |
| US-12570642-B2 | GLP-IR modulating compounds | GLP1R, GIPR, GPR119 | PRKDC 2860/4885ALDH1A1 3901/4885TSHR 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.